Home > News > Starpharma Holdings Limitedís VivaGel on the Fast Track to the Market
April 9th, 2007
Starpharma Holdings Limitedís VivaGel on the Fast Track to the Market
Starpharma Holdings Limited (ASX: SPL) makes and develops its products using nanotechnology. Its main drug is called VivaGel, a gel-based microbicide designed to protect women from sexually transmitted diseases, including HIV.
The gel has made it through Phase 1 clinical trials, and the United States Food & Drug Administration (FDA) has even granted the drug fast-track status ó and fast-track designation is nothing to scoff at. The term was coined in the FDA Modernization Act of 1997 in an effort to speed up the approval process for some worthy causes. The designation is reserved for new drugs that could address unmet medical needs and treat serious or life-threatening conditions.
Graphene rubber bands could stretch limits of current healthcare, new research finds August 19th, 2014
Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014
Scientists fold RNA origami from a single strand: RNA origami is a new method for organizing molecules on the nanoscale. Using just a single strand of RNA, this technique can produce many complicated shapes. August 14th, 2014
Iranian Scientists Stabilize Protein on Highly Stable Electrode Surface August 14th, 2014
Success in Intracellular Imaging of Cesium Distribution in Plants Used for Cesium Absorption August 19th, 2014
Сalculations with Nanoscale Smart Particles August 19th, 2014
Life on Mars? Implications of a newly discovered mineral-rich structure August 19th, 2014
Promising Ferroelectric Materials Suffer From Unexpected Electric Polarizations: Brookhaven Lab scientists find surprising locked charge polarizations that impede performance in next-gen materials that could otherwise revolutionize data-driven devices August 18th, 2014